Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $172,033.46 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of Precision BioSciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the sale, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at $500,096.29. This represents a 25.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The stock was sold at an average price of $8.19, for a total transaction of $24,668.28.

Precision BioSciences Price Performance

DTIL stock opened at $4.97 on Thursday. The firm has a market cap of $38.12 million, a P/E ratio of 82.85 and a beta of 1.51. The firm’s fifty day moving average is $5.62 and its 200 day moving average is $8.04. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DTIL shares. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Friday, January 10th.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC grew its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned about 0.86% of Precision BioSciences worth $591,000 as of its most recent SEC filing. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.